Andrea Gini

Andrea Gini

Auto-generated profile, based on publicly available information

Andrea Gini

Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Gut
Verified
Journal Article
Closed access
PDF file
EMEileen Morgan
Eileen Morgan
MAMelina Arnold
Melina Arnold
AGA Gini
A Gini
VLV Lorenzoni
V Lorenzoni
CCC J Cabasag
C J Cabasag
FBFreddie Bray
Freddie Bray
Objective Colorectal cancer (CRC) is the third most common cancer worldwide. The geographical and temporal burden of this cancer provides insights into risk factor prevalence and progress in cancer control strategies. We examine the current and future burden of CRC in 185 countries in 2020 and 2040. Methods Data on CRC cases and deaths were extracted from the GLOBOCAN database for the year 2020. Age-standardised incidence and mortality rates were calculated by sex, country, world region and Human Development Index (HDI) for 185 countries. Age-specific rates were also estimated. The predicted number of cases and deaths in 2040 were calculated based on global demographic projections by HDI. Results Over 1.9 million new CRC cases and 930 000 deaths were estimated in 2020. Incidence rates were highest in Australia/ New Zealand and European regions (40.6 per 100 000, males) and lowest in several African regions and Southern Asia (4.4 per 100 000, females). Similar patterns were observed for mortality rates, with the highest observed in Eastern Europe (20.2 per 100 000, males) and the lowest in Southern Asia (2.5 per 100 000, females). The burden of CRC is projected to increase to 3.2 million new cases and 1.6 million deaths by 2040 with most cases predicted to occur in high or very high HDI countries. Conclusions CRC is a highly frequent cancer worldwide, and largely preventable through changes in modifiable risk factors, alongside the detection and removal of precancerous lesions. With increasing rates in transitioning countries and younger adults, there is a pressing need to better understand and act on findings to avert future cases and deaths from the disease.

21 April 2022 in eClinicalMedicine
Verified
Journal Article
Open access
EMEileen Morgan
Eileen Morgan
MAMelina Arnold
Melina Arnold
MCM. Constanza Camargo
M. Constanza Camargo
AGAndrea Gini
Andrea Gini
AKAndrew T. Kunzmann
Andrew T. Kunzmann
ISIsabelle Soerjomataram
Isabelle Soerjomataram
To examine global patterns of gastric cancer in 2020 and the projected burden in 2040. Data on primary gastric cancer were extracted from the GLOBOCAN database for the year 2020. Age-standardized incidence and mortality rates were calculated by sex, country, world region and level of human development index (HDI) for 185 countries. The predicted burden of incidence and mortality in 2040 was calculated based on demographic projections. In total, ∼1.1 million new cases and 770,000 deaths of gastric cancer were estimated in 2020. Incidence rates were on average 2-fold higher in males than females (15.8 and 7.0 per 100,000, respectively) with variation across countries. Highest incidence rates were observed in Eastern Asia for both males and females (32.5 and 13.2, respectively); males residing in Japan (48.1), Mongolia (47.2) and Korea (39.7) had the highest rates in the world. Incidence was lowest in Africa with incidence rates < 5 per 100,000. Highest mortality rates were observed in Eastern Asia for both males (21.1) and females (8.8). A lower share of deaths was observed in very high HDI countries compared to medium and low HDI countries. The annual burden of gastric cancer is predicted to increase to ∼1.8 million new cases and ∼1.3 million deaths by 2040. These estimates of the global burden of gastric cancer pinpoint countries and regions of high incidence and mortality in need of cancer control initiatives. Primary prevention through eradication of H. pylori and behavioural changes such as reducing salt intake, smoking, obesity, and alcohol, remains key in stomach cancer control. No direct funding was received. All authors had access to the included study data and all authors agreed with the final decision to submit for publication.

1 February 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DHDenis Hadjiliadis
Denis Hadjiliadis
AKAlexander Khoruts
Alexander Khoruts
AZAnn G. Zauber
Ann G. Zauber
SHSarah E. Hempstead
Sarah E. Hempstead
PMPatrick Maisonneuve
Patrick Maisonneuve
KSKathy Sabadosa
Kathy Sabadosa

1 March 2020 in European Journal of Cancer
Verified
Journal Article
Open access
AGAndrea Gini
Andrea Gini
EJErik E.L. Jansen
Erik E.L. Jansen
NZNadine Zielonke
Nadine Zielonke
RMReinier G.S. Meester
Reinier G.S. Meester
CSCarlo Senore
Carlo Senore
JPJennifer Priaulx
Jennifer Priaulx
Populations differ with respect to their cancer risk and screening preferences, which may influence the performance of colorectal cancer (CRC) screening programs. This review aims to systematically compare the mortality effect of CRC screening across European regions. Six databases including Embase, Medline, Web of Science, PubMed publisher, Google Scholar and Cochrane Library were searched for relevant studies published before March 2018. Bibliographic searches were conducted to select studies assessing the effect of various screening tests (guaiac fecal occult blood test [gFOBT]; flexible sigmoidoscopy [FS]; fecal immunochemical test [FIT] and colonoscopy) on CRC mortality in Europe (PROSPERO protocol: CRD42016042433). Abstract reviewing, data extraction and risk of bias assessment were conducted independently by two reviewers. A total of 18 studies were included; of which, 11 were related to gFOBT, 4 to FS, 2 to FIT and 1 to colonoscopy; 8 were randomised clinical trials, and 10, observational studies, and an approximately equal number of studies represented Northern, Western and Southern European regions. Among individuals invited to screening, CRC mortality reductions varied from 8% to 16% for gFOBT and from 21% to 30% for FS. When studies with a high risk of bias were considered, ranges were more extensive. The estimated effectiveness of gFOBT and FS screening appeared similar across different European regions. CRC mortality impact of inviting individuals with similar adopted screening strategies (gFOBT or FS) may be consistent across several European settings.

9 April 2015 in European Journal of Epidemiology
Verified
Journal Article
Closed access
PDF file
LMLuigino DAL MASO
Luigino DAL MASO
NTNicola Torelli
Nicola Torelli
EBElisa Biancotto
Elisa Biancotto
MMMatteo Di Maso
Matteo Di Maso
AGAndrea Gini
Andrea Gini
Jerry PoleselJerry Polesel
Jerry Polesel

20 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Valli De ReValli De Re
Valli De Re
LCLAURA CAGGIARI
LAURA CAGGIARI
MZMARIANGELA DE ZORZI
MARIANGELA DE ZORZI
OROmbretta Repetto
Ombretta Repetto
AZAnna Linda Zignego
Anna Linda Zignego
PPPaolo De Paoli
Paolo De Paoli
The variability in the association of host innate immune response to Hepatitis C virus (HCV) infection requires ruling out the possible role of host KIR and HLA genotypes in HCV-related disorders: therefore, we therefore explored the relationships between KIR/HLA genotypes and chronic HCV infection (CHC) as they relate to the risk of HCV-related hepatocarcinoma (HCC) or lymphoproliferative disease progression. We analyzed data from 396 HCV-positive patients with CHC (n = 125), HCC (118), and lymphoproliferative diseases (153), and 501 HCV-negative patients. All were HIV and HBV negative. KIR-SSO was used to determine the KIR typing. KIR2DL5 and KIR2DS4 variants were performed using PCR and GeneScan analysis. HLA/class-I genotyping was performed using PCR-sequence-based typing. The interaction between the KIR gene and ligand HLA molecules was investigated. Differences in frequencies were estimated using Fisher’s exact test, and Cochran-Armitage trend test. The non-random association of KIR alleles was estimated using the linkage disequilibrium test. We found an association of KIR2DS2/KIR2DL2 genes, with the HCV-related lymphoproliferative disorders. Furthermore, individuals with a HLA-Bw6 KIR3DL1+ combination of genes showed higher risk of developing lymphoma than cryoglobulinemia. KIR2DS3 gene was found to be the principal gene associated with chronic HCV infection, while a reduction of HLA-Bw4 + KIR3DS1+ was associated with an increased risk of developing HCC. Our data highlight a role of the innate-system in developing HCV-related disorders and specifically KIR2DS3 and KIR2D genes demonstrated an ability to direct HCV disease progression, and mainly towards lymphoproliferative disorders. Moreover the determination of KIR3D/HLA combination of genes direct the HCV progression towards a lymphoma rather than an hepatic disease. In this contest IFN-α therapy, a standard therapy for HCV-infection and lymphoproliferative diseases, known to be able to transiently enhance the cytotoxicity of NK-cells support the role of NK cells to counterstain HCV-related and lymphoproliferative diseases.